Aytu Biopharma (AYTU) Net Equity Issued and Repurchased (2010 - 2023)

Aytu Biopharma (AYTU) has 10 years of Net Equity Issued and Repurchased data on file, last reported at -$10.1 million in Q2 2023.

• On a quarterly basis, Net Equity Issued and Repurchased fell 905.17% year-over-year to -$10.1 million in Q2 2023; TTM through Mar 2024 was -$9.7 million, a 175.46% decrease from a year earlier, with the FY2023 full-year figure at $2.9 million, down 75.2% from the prior year.
• Net Equity Issued and Repurchased for Q2 2023 stood at -$10.1 million, down from $1.4 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for AYTU reached as high as $12.8 million in Q2 2021 and fell as low as -$10.1 million in Q2 2023.
• Historically, Net Equity Issued and Repurchased has averaged $2.3 million across 3 years, with a median of $1.4 million in 2023.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 81.73% in 2023 and fell as far as 905.17% in 2023.
• Year by year, Net Equity Issued and Repurchased stood at $4.5 million in 2021, then slumped by 122.27% to -$1.0 million in 2022, then slumped by 905.17% to -$10.1 million in 2023.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were -$10.1 million in Q2 2023, $1.4 million in Q1 2023, and -$1.0 million in Q2 2022.